NCT05430464招募中不适用
A Randomized, Controlled, Split Face Study of a 1726 nm Laser for the Treatment of Acne Vulgaris
Cutera Inc.4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年7月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 4
- 主要终点
- Percent of subjects having at least a 1 point reduction on the Investigator Global Assessment Scale
研究概览
简要总结
The purpose of this study is to evaluate the onset, duration, efficacy and safety of the laser for the treatment of acne vulgaris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 50 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or Male, 16 to 50 years of age (inclusive).
- •Fitzpatrick Skin Type I-VI
- •Has clinically diagnosed acne vulgaris of moderate to severe on each hemiface and inflammatory acne lesions as determined by the blinded trained investigator (or qualified designee) using the Investigator's Global Assessment Scale.
- •Subject (and legally authorized representative/substitute decision maker if subject is incapable of providing informed consent) must be able to read, speak, and understand English and sign the Informed Consent Form.
- •Willing to stop using topical acne medications on the face for 2 weeks prior to baseline and systemic acne medications for 1 month prior to baseline and for the duration of the study.
- •Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
- •Willing to have very limited sun exposure (including avoiding tanning booths, sun lamps, sunbathing) and use an approved sunblock or sunscreen of SPF (Skin Protection Factor) 30 or higher on the face every day for the duration of the study, including the follow-up period.
- •Willing to have photographs taken of the face and agree to the use of photographs for presentation, educational or marketing purposes.
- •Agree to not undergo any other procedure(s) or add any new treatment modalities in the target area during the study.
排除标准
- •Has clinically diagnosed acne vulgaris of severity grade of clear, almost clear, or mild on at least one hemiface as determined by the blinded trained investigator (or qualified designee) using the Investigator's Global Assessment Scale.
- •Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
- •Prior treatment to the target area within 1 month of study participation including chemical peel, dermabrasion/microdermabrasion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.
- •Prior injection of botulinum toxin in the target area within 1 month of study participation and for the duration of the study.
- •Prior injection of collagen, hyaluronic acid filler or other dermal/tissue filler in the target area within 2 weeks of study participation.
- •Systemic use of retinoid, such as isotretinoin, within 6 months of study participation.
- •Started or changed hormonal contraception within 6 months of study participation or intends to start or change hormonal contraception through duration of the study. If subject has not changed hormonal contraception within 6 months of study participation and has intent of continuation through duration of this study, ok to enroll.
- •History of malignant tumors in the target area.
- •Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) or facial adornments (studs, piercings, tattoos) that may preclude treatments, photos or accurate lesion assessments in the target area.
- •Pregnant and/or breastfeeding or planning to become pregnant during the study.
- •Presence of any skin condition in the target area (e.g., eczema, psoriasis, dermatitis, rash, papulo-pustular rosacea, infection) that would interfere with the diagnosis or assessment of acne vulgaris.
- •Any medical condition that, in the opinion of the Investigator, would interfere with patient's participation in the full study protocol (e.g., severe Diabetes Mellitus or Cardiovascular Disease).
- •Suffering from diagnosed coagulation disorders or taking prescription anticoagulation medications.
- •History of diagnosed immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- •History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- •Known hypersensitivity to, history of allergic reaction to, or contraindication to Pro-Nox (or similar) if administered.
- •Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
- •History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.
- •History of radiation to the target area, currently undergoing treatment for skin cancer in the target area or undergoing systemic chemotherapy for the treatment of cancer.
- •History of diagnosed pigmentary disorders (including vitiligo) in the target area.
- •Facial tan or unable/unlikely to refrain from tanning on the face during the study.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
结局指标
主要结局
Percent of subjects having at least a 1 point reduction on the Investigator Global Assessment Scale
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
撤回
不适用
Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic AlopeciaAndrogenetic AlopeciaNCT05129254Montefiore Medical Center
已完成
4 期
Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic EyesMyopiaPresbyopiaHyperopiaNCT01387360Technolas Perfect Vision GmbH33
已完成
不适用
Effect of Low Level Laser Teraphy on Bone RegenerationAlveolar Ridge AugmentationNCT03179683Ugur GULSEN12
撤回
不适用
Thulium Laser and KeraFactor for the Treatment of Androgenetic AlopeciaAndrogenetic AlopeciaNCT04882969Montefiore Medical Center
已完成
2 期
Effect of Low-Level Laser on Pain and Healing of Donor Site Following Free Gingival GraftGingival RecessionNCT02896283Tehran University of Medical Sciences12